Resolvin D1 as a novel anti-inflammatory marker in manic, depressive and euthymic states of bipolar disorder

Basit Öğe Kaydı
dc.authoridKök Kendirlioğlu, Burcu/0000-0003-0632-1617en_US
dc.authoridilnem, mehmet cem/0000-0003-1614-9056en_US
dc.authoridKalelioğlu, Tevfik/0000-0001-9319-055Xen_US
dc.contributor.authorKök Kendirlioğlu, Burcu
dc.contributor.authorÖzpercin, Pelin Unalan
dc.contributor.authorOksuz, Özge Yuksel
dc.contributor.authorSozen, Şule
dc.contributor.authorCihnioğlu, Refik
dc.contributor.authorKalelioğlu, Tevfik
dc.contributor.authorIlnem, Mehmet Cem
dc.date.accessioned2024-07-12T21:37:42Z
dc.date.available2024-07-12T21:37:42Z
dc.date.issued2020en_US
dc.department[Belirlenecek]en_US
dc.description.abstractBackground: Resolvin D1 (RvD1) is a soluble mediator, which is the metabolite of docosahexaenoic acid (DHA), an omega-3 fatty acid. It is thought that RvD1 may contribute to the etiology of bipolar disorder (BD) because of its anti-inflammatory and antidepressant effect. In this study, it was aimed to compare the serum RvD1 levels of patients with BD diagnosed manic-depressive-euthymic episodes with those of healthy subjects. The secondary objective of this study is to investigate the relationship between RvD1 measures and inflammatory markers. Methods: We included 121 male patients with BD type I, 44 in a mania, 35 in depression and 42 in euthymic state, and 41 healthy controls. Serum RvD1 levels and inflammation indicators (CRP, neutrophil, leukocyte, and albumin) were measured. Results: When the RvD1 values of patients were compared, the median (interquartile range) RvD1 value was 11.2 (5.2) for manic patients, 11.2 (6.6) for depressive patients, 9.6 (5.6) for euthymic patients and 8.4 (7.7) for the control group. There were statistically significant differences between the groups in terms of RvD1 values (p?en_US
dc.identifier.doi10.1080/08039488.2019.1673480
dc.identifier.endpage88en_US
dc.identifier.issn0803-9488
dc.identifier.issn1502-4725
dc.identifier.issue2en_US
dc.identifier.pmid31575320en_US
dc.identifier.scopus2-s2.0-85074048725en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage83en_US
dc.identifier.urihttps://doi.org/10.1080/08039488.2019.1673480
dc.identifier.urihttps://hdl.handle.net/20.500.12415/6893
dc.identifier.volume74en_US
dc.identifier.wosWOS:000488410400001en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherTaylor & Francis Ltden_US
dc.relation.ispartofNordic Journal of Psychiatryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY04235
dc.subjectResolvin D1en_US
dc.subjectBipolar Disorderen_US
dc.subjectInflammationen_US
dc.subjectFatty Aciden_US
dc.subjectAntiinflammatoryen_US
dc.titleResolvin D1 as a novel anti-inflammatory marker in manic, depressive and euthymic states of bipolar disorderen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu